You are on Trendlyne India. Click here to go to United States website or make India as your default

105.70 1.70 (1.63%)

45.37% Fall from 52W High

1,507 BSE Volume

BSE 21 Apr, 2025 3:31 PM (IST)

Parnax Lab Key Metrics

Default
All financials are in INR Cr and price data in INR
VIEW MORE
Loading... You have run out of DVM views! Check usage
Subscribe now to see details
Medium Financial Strength
55.0 / 100
Affordable Valuation
73.0 / 100
Technically Neutral
47.5 / 100
Mid-range Performer These stocks may be affordable or expensive, based on their medium quality and mid-range technical score. However, their reasonable financials are successful in gathering some investor interest. View Similar Embed DVM

Parnax Lab Ltd. Live Price Chart

Fetching data ...

Parnax Lab Stock Analysis

Parnax Lab stock analysis with key metrics, changes, and trends.

Parnax Lab MetricVALUECHANGE %TRENDANALYSIS
Annual Revenue₹189.53 Cr12.56%positive

Annual Revenue rose 12.56%, in the last year to ₹189.53 Cr. Its sector's average revenue growth for the last fiscal year was 11.87%.

Annual Net Profit₹9.61 Cr11.5%positive

Annual Net Profit rose 11.5% in the last year to ₹9.61 Cr. Its sector's average net profit growth for the last fiscal year was 26.81%.

Price to Earning Ratio11.2-positive

Price to Earning Ratio is 11.2, lower than its sector PE ratio of 40.42.

Stock Price₹105.70-22.14%negative

Stock Price fell 22.14% and underperformed its sector by 45.69% in the past year.

Quarterly Revenue₹40.41 Cr21.13%negative

Quarterly Revenue fell 21.13% YoY to ₹40.41 Cr. Its sector's average revenue growth YoY for the quarter was 9.98%.

Quarterly Net profit₹1.21 Cr44.4%negative

Quarterly Net profit fell 44.4% YoY to ₹1.21 Cr. Its sector's average net profit growth YoY for the quarter was 20.25%.

Debt to Equity Ratio0.99-positive

Debt to Equity Ratio of 0.99 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

Return on Equity(ROE)13.42 %13.42%neutral

Return on Equity(ROE) for the last financial year was 13.42%, in the normal range of 10% to 20%.

Mutual Fund Holding0.00 %0%neutral

Mutual Fund Holding remained the same in the last quarter at 0%.

Promoter Share Holding72.30 %0%neutral

Promoter Share Holding stayed the same in the most recent quarter at 72.3%.

Interest Coverage Ratio4.56-positive

Interest Coverage Ratio is 4.56, higher than 1.5. This means that it is able to meet its interest payments comfortably with its earnings (EBIT).

Promoter Pledges9.41 %0%neutral

Promoter Pledges stayed the same in the last quarter at 9.41%.

VIEW LESS


Loading data..

Earnings Conference Calls, Investor Presentations and Annual Reports

Annual Report Mar-2024
Annual Report Mar-2023
Annual Report Mar-2022
Annual Report Mar-2021
Annual Report Mar-2020
Annual Report Mar-2019
Annual Report Mar-2018
Annual Report Mar-2017
Annual Report Mar-2016
Annual Report Mar-2015
Annual Report Mar-2014
Annual Report Mar-2013
Annual Report Mar-2012

Parnax Lab Ltd. - Company Profile

What does Parnax Lab Ltd. do?

Parnax Lab is engaged the business activities of manufacturing and export of Pharmaceutical Formulations.

Website: www.naxparlab.com

Parnax Lab Ltd. Management structure

All Gross Remunerations are in INR
Preet Kukreja
Company Secretary, Compliance Officer
-
2024-3-31
Gross Remuneration
Year
Mihir Prakash Shah
Executive Director, Chief Executive Officer
-
2024-3-31
Gross Remuneration
Year
Binoy Baiju Shah
Executive Director, Managing Director, Chief Financial Officer
-
2024-3-31
Gross Remuneration
Year

Parnax Lab Ltd. Board of directors

All Gross Remunerations are in INR
Mihir Prakash Shah
Director & Chief Executive Off
60 Lac
2024
Gross Remuneration
Year
Binoy Baiju Shah
Managing Director & CFO
60 Lac
2024
Gross Remuneration
Year
Ami M Shah
Non Executive Director
-
2024
Gross Remuneration
Year
T V Anantharaman
Independent Director
-
2024
Gross Remuneration
Year
Yogesh Varia
Independent Director
-
2024
Gross Remuneration
Year
Harish S Panpalia
Independent Director
-
2024
Gross Remuneration
Year

Parnax Lab Ltd. - company history

Parnax Lab Limited (Formerly Known as Krishna Deep Trade & Investment Ltd ) was incorporated in August, 1982. The Company changed the name from Krishna Deep Trade & Investment Ltd to Parnax Lab Limited effective on July 19, 2012. The Company is principally engaged in the business activities of manufacturing and export of Pharmaceutical Formulations. Initially, it was engaged in investment and financing activities. Naxpar Pharma Private Limited is Subsidiary Company of the Holding Company. With over two decades of rich experience behind it, the Naxpar Group is at the helm of innovation in the manufacturing of Pharmaceuticals, Cosmetics, Herbal/Ayurvedic formulations & Nutraceuticals (FSSAI) products. The Naxpar Group is headquartered in Mumbai, India. It is as a result of their diligence and perseverance that Naxpar's prowess in pharmaceutical manufacturing has seen exponential growth and achievement, significant milestones such as the coveted ISO 9002 status from RWTUV, Germany for following Good Quality Systems in manufacturing and marketing of formulations for domestic and international markets. Naxpar initially began as a single-establishment - indicative of its resounding success and growing client base, the Company now has state-of-the-art accredited manufacturing facilities with high speed packing lines in Silvassa, in Dadra & Nagar Haveli and Baddi in Himachal Pradesh. Naxpar's key strength is manufacturing finished formulations for multinationals in India and abroad and in emerging pharmaceutical markets such as Nigeria, Kazakhstan, Kenya, Mauritius etc. The WHO-approved and EHS-compliant Company is now well placed to venture into markets such as South East Asia, CIS, LatAm etc. where it is keen to establish its presence as a leading pharmaceuticals, cosmetics and herbal products manufacturer.

Parnax Lab Ltd. FAQ

How is Parnax Lab Ltd. today?
Parnax Lab Ltd. today is trading in the green, and is up by 1.63% at 105.70.
Parnax Lab Ltd. is currently trading up 1.63% on an intraday basis. In the past week the stock rose 5.65%. stock has been down -32.27% in the past quarter and fell -22.14% in the past year. You can view this in the overview section.